July 8, 2009 - High-Intensity-Focused Ultrasound (HIFU), which uses high-frequency sound waves to heat up tissue, is an experimental cancer therapy for prostate cancer that may be able to treat men without surgery and offer fewer side effects, according to the results of a study published in the British Journal of Cancer.

In the study, which took place at University College Hospital in London and the privately owned Princess Grace Hospital in London, treated a group of 172 men with prostate cancer that had not spread were treated under general anaesthetic with HIFU.

The men taking part in the trial were discharged on average five hours after receiving the HIFU treatment. Typically men with prostate cancer are treated with either surgery or radiotherapy. Surgery usually requires a two to three day inpatient stay and radiotherapy requires daily treatment as an outpatient for up to one month.

Of the initial group, 159 men were followed up a year later and 92 percent did not have any recurrence of prostate cancer. Although this was not a comparative study, it would be expected that traditional treatments for early prostate cancer of surgery or radiotherapy would show a similar percentage of men showing no recurrence of their prostate cancer one year on.

Less than one percent - one man of the 159 followed up - had incontinence. And 30-40 percent had impotence. None had any bowel problems.

Ahmed et al. High-Intensity-Focused Ultrasound in the treatment of primary prostate cancer: the first UK series. 1 July, 2009. British Journal of Cancer.

For more information: www.ukhifu.co.uk


Related Content

News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Ultrasound Women's Health

Sept. 3, 2026 — Royal Philips has introduced the eV14-2v transvaginal transducer, expanding its obstetrics and ...

Time September 04, 2026
arrow
News | Breast Imaging

Aug. 20, 2026 — Candelis, Inc. has announced a collaboration with GE HealthCare to support the distribution of Candelis ...

Time August 24, 2026
arrow
News | Clinical Trials

Aug.12, 2026 — Mendaera Inc. has announced results from a peer-reviewed study showing that its FDA-cleared Focalist ...

Time August 17, 2026
arrow
News | Radiation Therapy

Aug. 13, 2026 — An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence ...

Time August 17, 2026
arrow
Subscribe Now